{"id":"W3016538158","doi":"10.1016/s0140-6736(20)30262-2","title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Obinutuzumab; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Oncology; Leukemia; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006653304,0.0006216026,0.002734075,0.0000781299,0.0003180192,0.0001592398,0.0004489995,0.0002212772,0.0002700468],"category_scores_gemma":[0.00136904,0.0003123292,0.0003237611,0.0003987885,0.0005688317,0.0001444425,0.0001147711,0.0002891118,0.00007855],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05514649,"about_ca_system_score_gemma":0.04694984,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005934138,"about_ca_topic_score_gemma":0.0001566782,"domain_scores_codex":[0.9963879,0.0002234296,0.0006771117,0.0008509788,0.0006975305,0.001163038],"domain_scores_gemma":[0.9957272,0.002226883,0.0003008849,0.0009895345,0.000205268,0.0005502166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9883257,0.00009084071,0.000006492772,0.0003645125,0.001545015,0.0002224872,0.001324752,0.0001612372,0.000625034,0.0001203737,0.003796209,0.003417405],"study_design_scores_gemma":[0.8222634,0.02364718,0.000001232651,0.0001515695,0.001429321,0.0002310813,0.0003451397,0.133111,0.001687558,0.0000186887,0.01678656,0.0003272425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774411,0.002043964,0.0002721774,0.002532489,0.0003120853,0.01532989,0.0001529336,0.0002671828,0.00164818],"genre_scores_gemma":[0.9879795,0.0009762169,0.0003940468,0.0009632415,0.004741546,0.002695345,0.0001098367,0.0001277472,0.002012555],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1660622,"threshold_uncertainty_score":0.9999329,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1071913197879008,"score_gpt":0.3732692195852925,"score_spread":0.2660778997973917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}